How drug-drug interactions can impact managed care

American Journal of Managed Care

Volumn 10, Issue SUPPL. 4, 2004, Pages

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GENERIC DRUG; IMIPRAMINE; NORFLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGING; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; HEALTH CARE SYSTEM; HEART ARRHYTHMIA; HUMAN; MANAGED CARE; MEDICAID; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MANAGED CARE PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; TREATMENT OUTCOME; UNITED STATES;

EID: 3242778552     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Physicians' Desk Reference. Montvale, NJ: Thomson Healthcare; 2004.
2. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337-344.
3. Preskorn S, Silkey B, Shah R, Neff M, Jones T, Choi J. Complexity of outpatient medication use in relation to age and number of prescribers. JAMA. In press.
4. US Census Bureau. 2000.
5. Silkey B, Preskorn SH, Golbeck A, Shah R, Neff M, Jones T. Complexity of medication use among younger and older outpatients: the role of antidepressants. JAMA. In press.
6. Levy RH, Thummel KE, Trager WF, eds. Metabolic Drug Interactions. 1st ed. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2000.
7. Preskorn SH. Outpatient Management of Depression: A Guide for the Practitioner. 2nd ed. Caddo, Okla: Professional Communications, Inc; 1999.
8. Preskorn SH. Clinical Pharmacology of SSRI's. 1st ed. Caddo, Okla: Professional Communications, Inc; 1996.
9. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 1992;13:346-352.
10. Chen ZR, Irvine RJ, Bochner F, Somogyi AA. Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci. 1990;46: 1067-1074.
11. Sindrup SH, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther. 1990;48:686-693.
12. Maggs JL, Williams D, Pirmohamed M, Park BK. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther. 1995;275:1463-1475.
13. Shad M, Preskorn SH. Antidepressants. In: Levy R, Thummel K, Trager W, Hansten P, Eichelbaum M, eds. Metabolic Drug Interactions. Philadelphia, Pa: Lippincott Williams and Wilkins; 2004:563-577.
14. Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA. 1997;277: 1682.
15. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (Part I). J Psychiatr Pract. 2003;9:150-158.
16. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (Part II). J Psychiatr Pract. 2003;9:228-236.
17. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol. 1996;16:345-355.
18. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90-98.
19. Preskorn SH. Drug development in psychiatry and the human genome project: the explosion in knowledge and potential targets. J Pract Psych Behav Health. 2001; 7:336-340.
20. Preskorn SH. The human genome project and modern drug development in psychiatry. J Psychiatr Pract. 2000;6:272-276.
21. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001;2:161-166.
22. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77-87.
23. Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Rockville, Md: National Institutes of Health; 1999.
24. Preskorn SH. Drug approvals and withdrawals over the last 60 years. J Psychiatr Pract. 2002;8:41-50.
25. Preskorn SH, Flockhart D. 2004 guide to psychiatric drug interactions. Primary Psychiatry. 2004;11:39-60.